Stakeholders on June 15, 2026, discussed a new drug successfully attacks what was previously considered an undruggable mutation in pancreatic cancer nearly doubling patient.
Parallel reporting noted that Researchers and health authorities published findings adding to the scientific and medical evidence base.
Court and agency records outlined key points. Daraxonrasib targets a KRAS mutation in pancreatic cancer and nearly doubled patient survival rates in clinical trials.
Further rulings or announcements may be issued in coming days.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/top/health/